Literature DB >> 24452021

Population-level effects of suppressing fever.

David J D Earn1, Paul W Andrews, Benjamin M Bolker.   

Abstract

Fever is commonly attenuated with antipyretic medication as a means to treat unpleasant symptoms of infectious diseases. We highlight a potentially important negative effect of fever suppression that becomes evident at the population level: reducing fever may increase transmission of associated infections. A higher transmission rate implies that a larger proportion of the population will be infected, so widespread antipyretic drug use is likely to lead to more illness and death than would be expected in a population that was not exposed to antipyretic pharmacotherapies. We assembled the published data available for estimating the magnitudes of these individual effects for seasonal influenza. While the data are incomplete and heterogeneous, they suggest that, overall, fever suppression increases the expected number of influenza cases and deaths in the US: for pandemic influenza with reproduction number , the estimated increase is 1% (95% CI: 0.0-2.7%), whereas for seasonal influenza with , the estimated increase is 5% (95% CI: 0.2-12.1%).

Entities:  

Keywords:  antipyretic drugs; fever; influenza; transmission

Mesh:

Substances:

Year:  2014        PMID: 24452021      PMCID: PMC3906934          DOI: 10.1098/rspb.2013.2570

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  35 in total

Review 1.  Physiological rationale for suppression of fever.

Authors:  P A Mackowiak
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

2.  Increased virus shedding with aspirin treatment of rhinovirus infection.

Authors:  E D Stanley; G G Jackson; C Panusarn; M Rubenis; V Dirda
Journal:  JAMA       Date:  1975-03-24       Impact factor: 56.272

3.  The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence.

Authors:  G L Toms; J A Davies; C G Woodward; C Sweet; H Smith
Journal:  Br J Exp Pathol       Date:  1977-08

4.  Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections.

Authors:  K I Plaisance; S Kudaravalli; S S Wasserman; M M Levine; P A Mackowiak
Journal:  Pharmacotherapy       Date:  2000-12       Impact factor: 4.705

5.  Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza.

Authors:  Ashleigh R Tuite; Amy L Greer; Michael Whelan; Anne-Luise Winter; Brenda Lee; Ping Yan; Jianhong Wu; Seyed Moghadas; David Buckeridge; Babak Pourbohloul; David N Fisman
Journal:  CMAJ       Date:  2009-12-03       Impact factor: 8.262

6.  Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence.

Authors:  Karen M Starko
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

7.  Elevation of nasal viral levels by suppression of fever in ferrets infected with influenza viruses of differing virulence.

Authors:  R H Husseini; C Sweet; M H Collie; H Smith
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

Review 8.  Does influenza transmission occur from asymptomatic infection or prior to symptom onset?

Authors:  Eleni Patrozou; Leonard A Mermel
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

9.  The transmissibility and control of pandemic influenza A (H1N1) virus.

Authors:  Yang Yang; Jonathan D Sugimoto; M Elizabeth Halloran; Nicole E Basta; Dennis L Chao; Laura Matrajt; Gail Potter; Eben Kenah; Ira M Longini
Journal:  Science       Date:  2009-09-10       Impact factor: 47.728

10.  The ferret model for influenza.

Authors:  Yumiko Matsuoka; Elaine W Lamirande; Kanta Subbarao
Journal:  Curr Protoc Microbiol       Date:  2009-05
View more
  28 in total

Review 1.  The sociality-health-fitness nexus: synthesis, conclusions and future directions.

Authors:  Charles L Nunn; Meggan E Craft; Thomas R Gillespie; Mark Schaller; Peter M Kappeler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-05-26       Impact factor: 6.237

Review 2.  Fever and the thermal regulation of immunity: the immune system feels the heat.

Authors:  Sharon S Evans; Elizabeth A Repasky; Daniel T Fisher
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

Review 3.  Using Evolutionary Theory to Guide Mental Health Research.

Authors:  Zachary Durisko; Benoit H Mulsant; Kwame McKenzie; Paul W Andrews
Journal:  Can J Psychiatry       Date:  2016-02-12       Impact factor: 4.356

4.  Profiling the U.S. Sick Leave Landscape: Presenteeism among Females.

Authors:  Philip Susser; Nicolas R Ziebarth
Journal:  Health Serv Res       Date:  2016-03-07       Impact factor: 3.402

5.  Game theory of pre-emptive vaccination before bioterrorism or accidental release of smallpox.

Authors:  Chai Molina; David J D Earn
Journal:  J R Soc Interface       Date:  2015-06-06       Impact factor: 4.118

6.  How the epidemiology of disease-resistant and disease-tolerant varieties affects grower behaviour.

Authors:  Rachel E Murray-Watson; Nik J Cunniffe
Journal:  J R Soc Interface       Date:  2022-10-19       Impact factor: 4.293

Review 7.  Fever as an important resource for infectious diseases research.

Authors:  Juan José González Plaza; Nataša Hulak; Zhaxybay Zhumadilov; Ainur Akilzhanova
Journal:  Intractable Rare Dis Res       Date:  2016-05

8.  Virulence-mediated infectiousness and activity trade-offs and their impact on transmission potential of influenza patients.

Authors:  Brian McKay; Mark Ebell; Ariella Perry Dale; Ye Shen; Andreas Handel
Journal:  Proc Biol Sci       Date:  2020-05-13       Impact factor: 5.349

9.  Why Do We Feel Sick When Infected--Can Altruism Play a Role?

Authors:  Keren Shakhar; Guy Shakhar
Journal:  PLoS Biol       Date:  2015-10-16       Impact factor: 8.029

Review 10.  Thermal Restriction as an Antimicrobial Function of Fever.

Authors:  Arturo Casadevall
Journal:  PLoS Pathog       Date:  2016-05-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.